BHVN - Biohaven Pharmaceutical Holding Company Ltd.

NYSE - NYSE Delayed price. Currency in USD
Show:
Income statement
Balance sheet
Cash flow
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2019
31/12/2018
31/12/2017
31/12/2016
Total revenue
1,151
0
0
0
0
Operating expenses
Research development
359,740
344,673
189,951
89,441
55,529
Selling general and administrative
216,592
134,449
34,603
18,141
5,109
Total operating expenses
576,332
479,122
224,554
107,582
60,638
Operating income or loss
-575,605
-479,122
-224,554
-107,582
-60,638
Interest expense
46,460
39,291
11,764
906
385
Total other income/expenses net
-16,369
-9,973
-4,137
-17,696
-2,421
Income before tax
-638,434
-528,386
-240,455
-126,184
-63,444
Income tax expense
1,004
419
467
1,006
90
Income from continuing operations
-639,438
-528,805
-240,922
-127,190
-63,534
Net income
-639,438
-528,805
-240,922
-127,190
-63,677
Net income available to common shareholders
-639,438
-528,805
-240,922
-139,196
-63,677
Basic EPS
-
-10.91
-6.15
-5.00
-4.48
Diluted EPS
-
-10.91
-6.15
-5.00
-4.48
Basic average shares
-
48,490
39,188
27,846
14,215
Diluted average shares
-
48,490
39,188
27,846
14,215
EBITDA
-
-489,095
-228,691
-125,278
-63,054